Flow cytometry has become a pivotal technology in South Korea, driven by advancements in research and industrial applications. This technology enables high-throughput analysis of single cells, with applications ranging from clinical diagnostics to industrial biotechnology. South Korea’s dedication to innovation and significant R&D investments has accelerated the adoption of flow cytometry, with key players like Becton, Dickinson and Company, Danaher Corporation (Beckman Coulter), and Thermo Fisher Scientific Inc. playing prominent roles.
Despite challenges such as high costs and technological complexity, the flow cytometry market in South Korea exhibits promising growth, supported by government initiatives and increased healthcare and biotech investments. The market was valued at $82.12 million in 2024 and is projected to reach $244.49 million by 2033, growing at a compound annual growth rate (CAGR) of 12.89% during the forecast period (2024-2033). Investments in flow cytometry in South Korea increased significantly, rising by 23.23% from $431.3 million in 2020 to $531.5 million in 2021, reflecting its growing importance across clinical, research, and industrial domains.
Recent Developments
Industrial-Scale Developments
- January 2024: SML Meditree partnered with Sengenics to distribute its immune proteomics platform, KREX, in South Korea.
- February 2022: IDEXX Laboratories launched the Procyte One analyzer in South Korea, leveraging advanced flow cytometry laser technology.
Research-Scale Developments
- August 2023: Researchers at Seoul St. Mary’s Hospital received recognition for their work on minimal residual disease (MRD) monitoring using multi-parametric flow cytometry.
- January 2023: Eunpyeong St. Mary’s Hospital expanded its capabilities, including the addition of new flow cytometers.
These developments underscore the expanding role of flow cytometry in both research and clinical settings within South Korea.
Market Demand Drivers and Limitations
Demand Drivers:
- Increasing healthcare investments and biotechnology and pharmaceutical manufacturing in South Korea.
- Rising research and development expenditures in the country.
Limitations:
- High costs and reliance on imported technology.
Market Outlook and Competitive Strategy
The South Korean flow cytometry market is positioned for substantial growth, fueled by increased investments in healthcare and biotechnology, technological advancements, and expanding applications in diagnostics and research. Opportunities in automation, AI integration, and emerging clinical applications further enhance the market’s potential. Strategic collaborations and adherence to stringent regulatory standards will drive market growth over the next decade.
The report includes a detailed competitive benchmarking of key players, presenting a clear market landscape and outlining strategies such as partnerships, agreements, and collaborations to identify untapped revenue pockets. Key players include:
- Agilent Technologies, Inc.
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Cytek Biosciences, Inc.
- Danaher Corporation (Beckman Coulter)
- II-VI Incorporated
- Sony Group Corporation (Sony Biotechnology)
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
- Miltenyi Biotec
Key Topics Covered
- Market overview, dynamics, regulatory compliance, and technology landscape.
- Product mapping, competitive insights, and market segmentation by product, method, application, and end-users.
For Further Information
For more details on this report, visit ResearchAndMarkets.com.
